Artiva Biotherapeutics Surges 39.09% Amid Market Gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 Dec 25
Artiva Biotherapeutics Inc experienced a significant price increase of 39.09%, crossing above its 20-day SMA, in a market context where the Nasdaq-100 rose by 0.36% and the S&P 500 gained 0.27%.
This surge is attributed to Artiva Biotherapeutics rising 10.39% after hours, despite a regular session decline, amid broader market strength. The stock's movement suggests a positive sentiment towards biotech companies, particularly in light of recent developments in the sector.
The implications of this price movement indicate a potential shift in investor focus towards biotech stocks, as the overall market shows signs of strength, which could lead to further interest in Artiva Biotherapeutics and similar companies.
Analyst Views on ARTV
Wall Street analysts forecast ARTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTV is 16.50 USD with a low forecast of 10.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.470
Low
10.00
Averages
16.50
High
23.00
Current: 4.470
Low
10.00
Averages
16.50
High
23.00
About ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
